Canada Mobile Cardiac Telemetry (Mct) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Canada Mobile Cardiac Telemetry (MCT) Market Size

• The Canada mobile cardiac telemetry (MCT) market size was valued at USD 2.56 billion in 2024 and is expected to reach USD 6.01 billion by 2032, at a CAGR of 11.20% during the forecast period
• The market growth is largely fueled by the growing adoption and technological progress within connected healthcare devices and remote monitoring technologies, leading to increased digitalization in both hospital and home care settings
• Furthermore, rising patient demand for secure, user-friendly, and real-time cardiac monitoring solutions is establishing Mobile Cardiac Telemetry (MCT) as the preferred method for arrhythmia detection and continuous ECG tracking. These converging factors are accelerating the uptake of Canada Mobile Cardiac Telemetry (MCT) solutions, thereby significantly boosting the industry's growth

 Canada Mobile Cardiac Telemetry (MCT) Market Analysis

• Mobile Cardiac Telemetry (MCT) solutions, offering real-time remote cardiac monitoring, are increasingly vital components of modern cardiac care systems in both hospital and home settings due to their enhanced diagnostic accuracy, continuous monitoring capabilities, and seamless integration with digital health platforms
• The escalating demand for MCT devices is primarily fueled by the rising prevalence of cardiovascular diseases, growing aging population, and increasing preference for non-invasive, patient-friendly monitoring solutions
• Multi-channel segment dominated the Canada mobile cardiac telemetry (MCT) market with a market share of 62.5% in 2024, driven by its enhanced diagnostic accuracy, ability to simultaneously record multiple cardiac signals, and growing clinical preference for comprehensive data monitoring

Report Scope and Canada Mobile Cardiac Telemetry (MCT) Market Segmentation   

Canada Mobile Cardiac Telemetry (MCT) Market Trends

“Growing Need Due to Rising Cardiovascular Incidences and Remote Monitoring Adoption”

• The increasing prevalence of cardiovascular diseases, coupled with the growing demand for remote patient monitoring technologies, is a significant driver for the heightened demand for Mobile Cardiac Telemetry (MCT) solutions in Canada
  • For instance, in April 2024, Onity, Inc. (Honeywell International, Inc.) announced an advancement in IoT-based self-storage security, which reflects the broader trend of integrating advanced sensor technology—similar innovations are now being adapted in healthcare, particularly within Canada’s MCT sector to enable real-time cardiac data transmission and monitoring
• As the population ages and chronic conditions such as arrhythmias and atrial fibrillation become more prevalent, MCT devices offer critical benefits including continuous heart rhythm monitoring, real-time alerts, and timely interventions, which traditional Holter monitors may lack
• Furthermore, the rising use of telehealth platforms and digital health ecosystems is making MCT systems an essential component of remote healthcare delivery, supporting clinicians in making faster, data-driven decisions
• The convenience of real-time monitoring, wireless data transmission, and the ability to detect asymptomatic or intermittent cardiac events are key factors propelling the adoption of MCT in both hospital and homecare settings. The trend towards at-home diagnostics and the increasing availability of user-friendly, wearable MCT devices further contribute to market growth

Canada Mobile Cardiac Telemetry (MCT) Market Dynamics

Driver

“Enhanced Convenience Through Real-Time Data and Remote Monitoring”

• A significant and accelerating trend in the Canada mobile cardiac telemetry (MCT) market is the deepening integration with artificial intelligence (AI)-enabled analytics and seamless connectivity with digital health platforms and remote care ecosystems. This convergence of technologies is significantly enhancing user convenience and physician oversight of cardiac conditions
  • For instance, modern MCT devices used in Canada are now capable of automatically transmitting real-time ECG data to cloud-based platforms, enabling healthcare providers to receive immediate alerts on abnormal rhythms and take timely action without requiring in-person visits. Devices like those from Zio by iRhythm and Biotricity allow clinicians to review data remotely and adjust treatment plans with greater efficiency
• AI-powered features in MCT devices enable pattern recognition to detect arrhythmias such as atrial fibrillation or ventricular tachycardia more accurately. Over time, these systems learn from patient data, enhancing detection accuracy, reducing false positives, and providing actionable clinical insights. Furthermore, remote access capabilities give patients the convenience of being monitored from home, improving compliance and comfort
• The seamless integration of MCT systems with electronic health records (EHRs) and digital care platforms allows centralized access to diagnostic information, empowering cardiologists and primary care teams to collaborate effectively. Through a single dashboard, providers can track patient vitals, receive real-time alerts, and initiate follow-up procedures—streamlining care workflows and reducing clinical burden
• This trend toward more intelligent, intuitive, and connected cardiac monitoring is fundamentally reshaping expectations in both acute and long-term care settings. Consequently, companies such as Medtronic, InfoBionic, and Medicalgorithmics are advancing the development of MCT solutions with enhanced analytics, real-time transmission, and interoperability with digital health ecosystems
• The demand for MCT devices that offer seamless remote monitoring and data-driven insights is growing rapidly across both home healthcare and clinical environments, as patients and providers increasingly prioritize continuous, convenient, and proactive cardiac care

Restraint/Challenge

“Concerns Regarding Data Privacy and High Initial Costs”

• Concerns surrounding the data privacy and cybersecurity vulnerabilities of connected medical devices, including MCT systems, pose a significant challenge to broader market penetration. As MCT devices transmit sensitive patient data over networks, they are susceptible to breaches, raising anxieties among providers and patients
  • For instance, high-profile reports of health data leaks have made some stakeholders cautious about relying entirely on remote cardiac monitoring tools such as MCT
• Addressing these cybersecurity concerns through end-to-end encryption, compliance with Canadian privacy laws (e.g., PIPEDA), and regular software updates is crucial for building trust. Companies such as iRhythm and BioTelemetry (a Philips company) highlight their secure data handling protocols and real-time monitoring capabilities to reassure both clinicians and patients
• In addition, the relatively high initial cost of advanced MCT systems compared to conventional monitoring options can be a barrier to adoption for budget-constrained healthcare facilities, especially in rural or underfunded areas. While basic models are becoming more accessible, premium features such as AI-driven diagnostics or multi-parameter tracking often involve a higher price point
• While healthcare reimbursement policies are evolving to support remote monitoring, the perception of MCT as a high-cost solution may still hinder rapid adoption. Overcoming these challenges through improved cybersecurity, physician and patient education, and the development of more affordable MCT solutions will be vital for sustained market growth

Canada Mobile Cardiac Telemetry (MCT) Market Scope

The market is segmented on the basis of type, technology, cellular connection, indication, end user and distribution channel.

• By Type

On the basis of type, the Canada mobile cardiac telemetry (MCT) market is segmented into multi-channel and single-channel. The multi-channel segment dominated the largest market revenue share of 62.5% in 2024, driven by its enhanced diagnostic accuracy, ability to simultaneously record multiple cardiac signals, and growing clinical preference for comprehensive data monitoring.

The single-channel segment is expected to witness the fastest CAGR of 20.3% from 2025 to 2032, owing to its cost-effectiveness, compact design, and ease of use in home healthcare settings.

• By Technology

On the basis of technology, the Canada mobile cardiac telemetry (MCT) market is segmented into lead based, patch based, and flex based. The lead based segment held the largest market share of 48.1% in 2024 due to its proven clinical reliability and widespread usage.

The patch based segment is projected to grow at the fastest CAGR of 22.6% from 2025 to 2032, driven by comfort, wireless design, and improved patient compliance.

• By Cellular Connection

On the basis of cellular connection, the Canada mobile cardiac telemetry (MCT) market is segmented into wireless (Wi-Fi) and Bluetooth (BT). The wireless (Wi-Fi) segment dominated with the largest market revenue share of 57.4% in 2024, supported by widespread internet access and real-time remote connectivity.

The Bluetooth (BT) segment is expected to register the fastest CAGR of 19.1% from 2025 to 2032, owing to energy efficiency, seamless smartphone integration, and peer-to-peer functionality.

• By Indication

On the basis of indication, the Canada mobile cardiac telemetry (MCT) market is segmented into angina pectoris, bradycardia arrhythmias, myocardial infarction, atrial flutter, pre-mature ventricular contractions, ventricular tachycardia, control atrial fibrillation, atherosclerosis, heart failure, and others. The control atrial fibrillation segment held the largest market share of 24.3% in 2024, reflecting the rising burden of AFib in Canada.

The ventricular tachycardia segment is projected to witness the fastest CAGR of 21.5% from 2025 to 2032, driven by growing concerns over sudden cardiac events and the demand for continuous monitoring solutions.

• By End User

On the basis of end user, the Canada mobile cardiac telemetry (MCT) market is segmented into home healthcare, hospitals, independent diagnostic testing facility (IDTF), cardiac centers, ambulatory surgical centers, and others. The hospitals segment accounted for the largest revenue share of 36.9% in 2024, supported by advanced infrastructure and rising in-patient cardiac diagnostics.

The home healthcare segment is expected to register the fastest CAGR of 23.2% from 2025 to 2032 due to increasing remote care adoption and patient convenience in chronic disease management.

• By Distribution Channel

On the basis of distribution channel, the Canada mobile cardiac telemetry (MCT) market is segmented into direct sales and others. The direct sales segment dominated the market with a revenue share of 68.7% in 2024, driven by preference for direct procurement and reliability in device servicing.

The others segment is anticipated to expand at a CAGR of 17.9% from 2025 to 2032, driven by the rise of digital procurement platforms and third-party distributors.

Canada Mobile Cardiac Telemetry (MCT) Market Regional Analysis

• The Canada mobile cardiac telemetry (MCT) market captured the largest revenue share of 15.2% within North America in 2024, fueled by increased adoption of remote patient monitoring programs and rising government initiatives supporting digital health transformation. Canadian healthcare providers are increasingly integrating MCT devices into post-discharge care plans to improve cardiac outcomes and reduce hospital readmissions.
• The country’s aging population and high incidence of arrhythmias such as atrial fibrillation are further driving demand. In addition, the growth of home healthcare services and advancements in cellular connectivity across remote regions of Canada support the rapid deployment and effectiveness of MCT solutions.
• The presence of domestic players such as Canadian Cardiac Care and collaborations with global med-tech firms are also contributing significantly to the market’s expansion.

Canada Mobile Cardiac Telemetry (MCT) Market Share

The Canada mobile cardiac telemetry (MCT) industry is primarily led by well-established companies, including:

• BIOTRONIK (Germany)
• Biotricity (U.S.)
• Zio by iRhythm Technologies, Inc. (U.S.)
• Canadian Cardiac Care (Canada)
• Corvitals (U.S.)
• ACS Diagnostics (U.S.)
• Hill-Rom Services, Inc. (U.S.)
• Infobionic (U.S.)
• MEDICALGORITHMICS.COM (Poland)
• Medtronic (Ireland)
• Medeia (France)
• Laboratory Corporation of America Holdings (U.S.)
• ScottCare Corporation (U.S.)
• Abbott (U.S.)
• BioTelemetry (U.S.)

Latest Developments in Canada Mobile Cardiac Telemetry (MCT) Market

• In March 2021, Laboratory Corporation of America Holdings (LabCorp) was honored in Fast Company's "2021 Most Innovative Companies" list, highlighting its excellence in science, innovation, and healthcare. LabCorp's significant contributions in combating COVID-19 through advanced testing underline its commitment to global health. This dedication extends to its role in advancing technologies such as mobile cardiac telemetry (MCT) in healthcare solutions
• In May 2021, VitalConnect launched the VitalPatch RTM, a mobile cardiac telemetry solution tailored for diverse cardiac monitoring requirements. Featuring a versatile and customizable platform, it exemplifies innovation in the field of mobile cardiac telemetry (MCT), addressing evolving healthcare demands with advanced technology
• In June 2023, ZOLL Medical Corporation, an Asahi Kasei company, announced the launch of its next-generation mobile cardiac telemetry (MCT) solution, designed to enhance arrhythmia detection and improve patient outcomes. The advanced system incorporates real-time ECG monitoring and streamlined data transmission, enabling faster clinical decision-making. This launch underscores ZOLL’s continued commitment to delivering innovative, reliable cardiac monitoring technologies that support better cardiovascular care

SKU-63321